Key result
Chemoradiation with maintenance taxanes linked to ~44% higher progression-free survival at one year in scalp angiosarcoma.
Why the study?
Cutaneous angiosarcoma is rare and aggressive, and the efficacy of CCRT with maintenance taxane chemotherapy for localized scalp angiosarcoma without cervical lymph node metastases needed retrospective analysis.
Does concurrent chemoradiation with maintenance chemotherapy using taxanes improve survival in patients with localized angiosarcoma of the scalp without cervical lymph node metastases?
Cohort (n=19)
No
Does concurrent chemoradiation with maintenance chemotherapy using taxanes improve survival in patients with localized angiosarcoma of the scalp without cervical lymph node metastases?
Concurrent chemoradiation with maintenance chemotherapy using taxanes may be an effective treatment strategy for localized angiosarcoma of the scalp.
May support taxane chemoradiation in localized scalp angiosarcoma; hypothesis-generating and requires randomized confirmation.
Cutaneous angiosarcoma is a rare aggressive malignant tumor. Concurrent chemoradiation (CCRT) with maintenance chemotherapy using taxanes is one of the primary treatments. The aim of the present study was to retrospectively analyze the efficacy of CCRT with maintenance chemotherapy using taxanes in localized angiosarcoma of the scalp without cervical lymph node metastases. A total of 19 patients treated with radiation therapy for localized angiosarcomas of the scalp without cervical lymph node metastases were enrolled. The overall survival (OS), progression-free survival (PFS), and local control (LC) rates were calculated using Kaplan-Meier analysis. Univariate analyses were performed for various potential prognostic factors for OS, PFS, and LC. The median radiation dose was 70 Gy (range, 60-70 Gy), and the fractional dose was 2 Gy. Radiation therapy alone, radiation therapy + interleukin-2, surgery + CCRT with maintenance chemotherapy, CCRT with maintenance chemotherapy, and CCRT without maintenance chemotherapy were administered to 2, 4, 2, 9 and 2 patients, respectively. The 1- and 3-year OS, PFS, and LC rates were 88 and 52%, 47 and 33%, and 74 and 56%, respectively. CCRT with maintenance chemotherapy and surgery were significant prognostic factors for PFS (P=0.036 and 0.025, respectively). Therefore, CCRT with maintenance chemotherapy using taxanes might be effective in treating localized angiosarcomas of the scalp without cervical lymph node metastases.
No takes yet. Share an insight, caveat, or question.
Ihara et al. (2019) conducted a cohort in Localized angiosarcoma of the scalp without cervical lymph node metastases (n=19). Concurrent chemoradiation (CCRT) with maintenance chemotherapy using taxanes vs. Other treatments (radiation therapy alone, radiation therapy + IL-2, or CCRT without maintenance chemotherapy) was evaluated on Progression-free survival (1-year) (p=0.036). Concurrent chemoradiation with maintenance taxane chemotherapy significantly improved progression-free survival compared to other treatments in patients with localized angiosarcoma of the scalp (1-year PFS 69% vs 25%, p=0.036).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: